DAX24.856 -0,5%Est506.036 -0,2%MSCI World4.343 -0,1%Top 10 Crypto8,5100 -0,4%Nas23.066 -0,2%Bitcoin56.427 +0,1%Euro1,1866 -0,1%Öl69,53 -0,1%Gold5.061 -0,5%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Siemens Energy ENER6Y Gerresheimer A0LD6E SAP 716460 Rheinmetall 703000 Deutsche Telekom 555750 NVIDIA 918422 BASF BASF11 Lufthansa 823212 Commerzbank CBK100 Amazon 906866 Microsoft 870747 Allianz 840400 DroneShield A2DMAA Bayer BAY001 Novo Nordisk A3EU6F
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Asiens Börsen uneins -- Mercedes-Benz mit Gewinneinbruch -- Siemens erhöht Ergebnisprognose -- Deutsche Börse meldet Rekordzahlen -- Lufthansa, thyssenkrupp, Cisco im Fokus
Top News
Analysten: Gold und Silber werden immer mehr zu einem Spekulationsobjekt Analysten: Gold und Silber werden immer mehr zu einem Spekulationsobjekt
DAX am Donnerstag mit Startplus erwartet - 25.000-Punkte-Marke bleibt im Blickpunkt DAX am Donnerstag mit Startplus erwartet - 25.000-Punkte-Marke bleibt im Blickpunkt
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Noch bis 14. April bei der Commerzbank gebührenfrei in Vanguard-ETFs investieren

Amgen Aktie

Kaufen
Verkaufen
Amgen Aktien-Sparplan
308,75 EUR -1,15 EUR -0,37 %
FSE
366,46 USD +1,87 USD +0,51 %
BTT
Amgen jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.165,33 Mrd. EUR

KGV23,00Div. Rendite2,91%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN867900

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS0311621009

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolAMGN

Amgen Aktien News

DatumMeistgelesen
PR NewswireAMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
PR NewswireAMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER
PR NewswireAMGEN TO WEBCAST INVESTOR CALL AT ESMO 2023
PR NewswireAMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023
PR NewswireAMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC
PR NewswireLarge-scale proteomics in population-based studies from UK and Iceland
PR NewswireLarge-scale proteomics in population-based studies from UK and Iceland
PR NewswireLarge-scale proteomics in population-based studies from UK and Iceland
PR NewswireLarge-scale proteomics in population-based studies from UK and Iceland
PR NewswireAMGEN LAUNCHES PARTNERS OF CHOICE NETWORK OF EIGHT LEADING ONCOLOGY ACADEMIC CENTERS
PR NewswireAMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC
PR NewswireAMGEN TO PRESENT AT THE MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE AND THE CITI GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN PRESENTS LATE-BREAKING PHASE 2 OLPASIRAN DATA AT ESC 2023
PR NewswireAMGEN TO DISCUSS APPLICATION FOR LUMAKRAS® (SOTORASIB) FOR THE TREATMENT OF KRAS G12C-POSITIVE NSCLC AT FDA ADVISORY COMMITTEE MEETING
MyDividendsAmgen gibt Dividende für das dritte Quartal bekannt
PR NewswireAMGEN ANNOUNCES 2023 THIRD QUARTER DIVIDEND
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2023 SECOND QUARTER FINANCIAL RESULTS
PR NewswireFDA GRANTS FULL APPROVAL FOR BLINCYTO® (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
PR NewswireAMGEN TO PRESENT AT THE GOLDMAN SACHS 44TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023
PR NewswireAMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023
PR NewswireAMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) IN PSORIATIC ARTHRITIS AT EULAR 2023
PR NewswireAMGEN TO PRESENT AT THE TD COWEN 4TH ANNUAL ONCOLOGY INNOVATION SUMMIT
PR NewswireAMGEN RESPONDS TO FTC ACTION RE: PROPOSED ACQUISITION OF HORIZON THERAPEUTICS
PR NewswireAMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE
PR NewswireAMGN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 12, 2023 in the Class Action Filed on Behalf of Amgen Inc. Shareholders
PR NewswireAMGN FINAL DEADLINE MAY 12: ROSEN, A TOP RANKED LAW FIRM, Encourages Amgen Inc. Investors to Secure Counsel Before Important Friday Deadline in Securities Class Action - AMGN
PR NewswireNEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE
PR NewswireAMGEN SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amgen To Contact Him Directly To Discuss Their Options
PR NewswireAMGEN TO PRESENT AT THE 2023 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN
PR NewswireAMGN Investors Have Opportunity to Lead Amgen Inc. Securities Fraud Lawsuit
PR NewswireKessler Topaz Meltzer & Check, LLP Reminds Amgen Inc. Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit
PR NewswireAMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS
PR NewswireAMGN LAWSUIT ALERT: Levi & Korsinsky Notifies Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN
PR NewswireSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Amgen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 12, 2023 - (NASDAQ: AMGN)
PR NewswireAMGEN INC. (NASDAQ: AMGN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amge...

Amgen News

Amgen News: auf dieser Seite finden Sie alle Amgen News und Nachrichten zur Amgen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Amgen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Amgen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.